Quantcast

Latest acute leukemia Stories

2014-02-13 10:35:34

Cancer researchers led by stem cell scientist Dr. John Dick have discovered a pre-leukemic stem cell that may be the first step in initiating disease and also the culprit that evades therapy and triggers relapse in patients with acute myeloid leukemia (AML). The research, published online today in Nature is a significant leap in understanding the steps that a normal cell has to go through as it turns into AML, says Dr. Dick, and sets the stage to advance personalized cancer medicine by...

2014-02-10 11:13:59

Analyzing the genomes of twin 3-year-old sisters – one healthy and one with aggressive leukemia – led an international team of researchers to identify a novel molecular target that could become a way to treat recurring and deadly malignancies. Scientists in China and the United States report their findings online Feb. 9 in Nature Genetics. The study points to a molecular pathway involving a gene called SETD2, which can mutate in blood cells during a critical step as DNA is being...

2014-02-09 12:20:14

CINCINNATI, Feb. 9, 2014 /PRNewswire-USNewswire/ -- Analyzing the genomes of twin 3-year-old sisters - one healthy and one with aggressive leukemia - led an international team of researchers to identify a novel molecular target that could become a way to treat recurring and deadly malignancies. (Logo: http://photos.prnewswire.com/prnh/20110406/MM79025LOGO) Scientists in China and the United States report their findings online Feb. 9 in Nature Genetics. The study points to a...

2014-02-04 08:33:18

SAN DIEGO, Feb. 4, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Leerink Global Healthcare Conference to be held at the Waldorf Astoria in New York City, February 12-13, 2014. Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug candidate,...

2014-01-30 08:30:59

FT. MYERS, Fla., Jan. 30, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic and molecular testing services, announced today that it has validated and launched a series of NeoTYPE cancer profiling tests covering 22 different categories of cancer. Each of these tests is designed to investigate the most common and actionable genomic abnormalities reported for that particular tumor. The 22 categories of tumors covered in this series of...

2014-01-30 04:21:54

- Trial Sponsored by Cardiff University and Supported by Cancer Research UK - SEATTLE, Jan. 30, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene. Mutation of the FLT3 gene is found in approximately one-third of AML patients and is an independent risk factor for...

2014-01-29 13:13:53

Genetically engineered mouse model validates the mutant IDH2 protein as candidate for targeted anticancer therapies; provides new tool for future investigations In recent years, mutations in two metabolic enzymes, isocitrate dehydrogenase-1 and 2 (IDH1 and IDH2), have been identified in approximately 20 percent of all acute myeloid leukemias (AML). As a result, mutant IDH proteins have been proposed as attractive drug targets for this common form of adult leukemia. Now a scientific team...

2014-01-23 16:24:44

Grant Program Addresses Three Critical Areas of Blood Cancer Research WHITE PLAINS, N.Y., Jan. 23, 2014 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today is pleased to announce the fourteen researchers who will receive funding through the Quest for Cures program - a new grant program that addresses three critical areas of blood cancer research. The three priority areas are: monitoring tumor cell heterogeneity and its contribution to response or resistance to therapy; molecular...

2014-01-23 08:30:32

- BL-8040 previously received Orphan Drug Designation for treatment of Acute Myeloid Leukemia - JERUSALEM, Jan. 23, 2014 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received notice from the U.S. Food & Drug Administration (FDA) confirming an Orphan Drug Designation of BL-8040 as a treatment for stem cell...

2014-01-16 16:23:55

Five Distinguished Researchers Receive First-Time Grant WHITE PLAINS, N.Y., Jan. 16, 2014 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today is pleased to announce the researchers who will receive funding through The Screen to Lead program - a new grant program to support drug discovery specifically directed toward medicinal chemistry and/or drug target screening in blood cancers. LLS recognizes investigators' significant need for resources to develop small molecules...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related